Randomized trial assessing worsening renal function with dapagliflozin addition in acute decompensated heart failure: ROAD-ADHF trial

Back

ESC Professional Premium Access

Randomized trial assessing worsening renal function with dapagliflozin addition in acute decompensated heart failure: ROAD-ADHF trial

Session: Further Insights into SGLT2i treatment for heart failure

Topic: Pharmacotherapy

Speaker: Doctor S. Kawanami (Sakai, JP)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Shodai Kawanami

Osaka Rosai Hospital, Sakai (Japan)

0 follower

5 more presentations in this session

Effects of dapagliflozin according to QRS duration across the spectrum of LVEF: An analysis of DAPA-HF and DELIVER

Speaker: Associate Professor A. Abdin (Homburg, DE)

The effects of SGLT2 inhibitors on right ventricle functions in heart failure patients: update meta-analysis of the current literature

Speaker: Doctor A. Erdem (Istanbul, TR)

Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial

Speaker: Assistant Professor J. Naser (Rochester, US)

Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study

Speaker: Associate Professor S. Bu (Uijeongbu, KR)

Effectiveness of empagliflozin in patients with heart failure and COPD: Results from EMPEROR-Preserved and EMPEROR-Reduced

Speaker: Professor S. von Haehling (Goettingen, DE)

Access the full session

Further Insights into SGLT2i treatment for heart failure

Speakers: Doctor S. Kawanami, Associate Professor A. Abdin, Doctor A. Erdem, Assistant Professor J. Naser, Associate Professor S. Bu...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources